{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:36:47Z","timestamp":1760575007076,"version":"build-2065373602"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640"],"award-info":[{"award-number":["IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640","IHS-1507-31640"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012464","name":"Kaleida Health Foundation","doi-asserted-by":"publisher","award":["Troup Fund","Troup Fund","Troup Fund","Troup Fund"],"award-info":[{"award-number":["Troup Fund","Troup Fund","Troup Fund","Troup Fund"]}],"id":[{"id":"10.13039\/100012464","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hybrid effectiveness-implementation designs evaluate the effectiveness and implementation of interventions. We retrospectively evaluated the implementation of a stepped-wedge cluster randomized controlled trial of a facilitated telemedicine model (experimental) integrated into opioid treatment programs (OTPs) compared to offsite referral (control) for hepatitis C virus (HCV) treatment. The trial period was March 2017\u2013October 2022. We compared organizational and implementation characteristics associated with an HCV cure and with high satisfaction with healthcare delivery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used the <jats:italic>R<\/jats:italic>each, <jats:italic>E<\/jats:italic>ffectiveness, <jats:italic>A<\/jats:italic>doption, <jats:italic>I<\/jats:italic>mplementation, <jats:italic>M<\/jats:italic>aintenance (RE-AIM) framework to guide data collection and evaluation. We evaluated the clinical effectiveness outcome (HCV cure) and patient-centered outcomes (changes between in-person and telemedicine patient satisfaction questionnaire subscales: Time Spent With Doctor and General Satisfaction). We evaluated 7 organizational and 16 implementation variables. We used random forests to obtain a list of variables with total importance weight of at least 95%. We subsequently conducted a configurational comparative method of coincidence analysis (CNA) to identify the variable combinations that are associated with the best outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The effectiveness of <jats:italic>reach<\/jats:italic> was enhanced by site identification of HCV RNA positive individuals. We found that low patient load per provider or counselor, site liaison presence, and high case manager availability increased clinical <jats:italic>effectiveness<\/jats:italic> (i.e., HCV cure). <jats:italic>Adoption and implementation<\/jats:italic>, assessed by high healthcare delivery satisfaction among participants in both arms, was associated with site liaisons, frequent case manager onsite presence and consistency, and low provider patient volume. Among telemedicine participants, onsite notifications and provider involvement in recruitment were additional variables associated with high healthcare satisfaction. In referral, providing patient education, low counselor patient volume, case manager involvement in site activities, and high case manager education levels were additional variables associated with high healthcare delivery satisfaction. Intervention <jats:italic>maintenance<\/jats:italic> has occurred at 10 sites.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Compared to referral, facilitated telemedicine requires fewer variables for high effectiveness and patient satisfaction. The frequent onsite presence and consistency of the case manager and low provider and counselor volumes improved outcomes among both approaches. Improved outcomes among referral participants required more publicity, patient education, higher case manager education, more involvement in site activities, and occurred in university-affiliated sites.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Clintrials.gov registration number NCT02933970; Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals Full Text View ClinicalTrials.gov.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12906-025-05138-9","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:23:53Z","timestamp":1760523833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Opioid treatment program-integrated facilitated telemedicine for hepatitis C treatment: a hybrid effectiveness-implementation analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Andrew H.","family":"Talal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianthi","family":"Markatou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Zeremski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpan","family":"Dharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saliyah G.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Silber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan N.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"5138_CR1","doi-asserted-by":"crossref","first-page":"103622","DOI":"10.1016\/j.jbi.2020.103622","volume":"112","author":"AH Talal","year":"2020","unstructured":"Talal AH, Sofikitou EM, Jaanimagi U, Zeremski M, Tobin JN, Markatou M. A framework for patient-centered telemedicine: application and lessons learned from vulnerable populations. J Biomed Inf. 2020;112:103622.","journal-title":"J Biomed Inf"},{"key":"5138_CR2","unstructured":"Henderson K, Winkler Y, Wyatt R, American Telemedicine Association Advisory Group on Using. Telehealth to Eliminate Disparties and Inequalities. A Framework for Eliminating Health Disparities Using Telehealth. Available at: https:\/\/wwwamericantelemedorg\/resources\/a-framework-for-eliminating-health-disparities-using-telehealth\/. Accessed 8 Oct 2023."},{"issue":"5","key":"5138_CR3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/jama.2020.25706","volume":"325","author":"A Mehrotra","year":"2021","unstructured":"Mehrotra A, Bhatia RS, Snoswell CL. Paying for telemedicine after the pandemic. JAMA. 2021;325(5):431\u20132.","journal-title":"JAMA"},{"issue":"14","key":"5138_CR4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","volume":"69","author":"AB Ryerson","year":"2020","unstructured":"Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: newly reported acute and chronic hepatitis C Cases - United States, 2009\u20132018. MMWR Morb Mortal Wkly Rep. 2020;69(14):399\u2013404.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"5138_CR5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"MG Ghany","year":"2020","unstructured":"Ghany MG, Morgan TR, Hepatitis AASLD-IDSA. Guidance Panel. Hepatitis C guidance 2019 update: American association for the study of liver diseases\u2013Infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686\u2013721.","journal-title":"Hepatology"},{"issue":"15","key":"5138_CR6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2023.3692","volume":"329","author":"RL Fleurence","year":"2023","unstructured":"Fleurence RL, Collins FS. A National hepatitis C elimination program in the united states: a historic opportunity. JAMA. 2023;329(15):1251\u20132.","journal-title":"JAMA"},{"issue":"2","key":"5138_CR7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/PHH.0000000000001808","volume":"30","author":"AH Talal","year":"2024","unstructured":"Talal AH, Dharia A, Kapadia SN, Tyson GL, Birch S, Zerzan-Thul J, et al. Hepatitis C virus elimination programs in Louisiana and washington: importance of screening and surveillance systems. J Public Health Manag Pract. 2024;30(2):208\u201312.","journal-title":"J Public Health Manag Pract"},{"key":"5138_CR8","unstructured":"U.S. Department of Health and Human Services. Viral hepatitis national strategic plan for the United States: a roadmap to elimination (2021\u20132025) 2021. Available from: https:\/\/www.hhs.gov\/sites\/default\/files\/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf. Accessed 25 Oct 2023."},{"key":"5138_CR9","doi-asserted-by":"crossref","unstructured":"Wester C, Osinubi A, Kaufman HW, Symum H, Meyer WA 3rd, Huang X, et al. Hepatitis C virus clearance cascade - United States, 2013\u20132022. MMWR Morb Mortal Wkly Rep. 2023;72(26):716\u201320.","DOI":"10.15585\/mmwr.mm7226a3"},{"issue":"16","key":"5138_CR10","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2024.2452","volume":"331","author":"AH Talal","year":"2024","unstructured":"Talal AH, Markatou M, Liu A, Perumalswami PV, Dinani AM, Tobin JN, et al. Integrated hepatitis C-Opioid use disorder care through facilitated telemedicine: A randomized trial. JAMA. 2024;331(16):1369\u201378.","journal-title":"JAMA"},{"issue":"3","key":"5138_CR11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/tmj.2022.0189","volume":"29","author":"AH Talal","year":"2023","unstructured":"Talal AH, Sofikitou EM, Wang K, Dickerson S, Jaanimagi U, Markatou M. High satisfaction with patient-centered telemedicine for hepatitis C virus delivered to substance users: a mixed-methods study. Telemed J E Health. 2023;29(3):395\u2013407.","journal-title":"Telemed J E Health"},{"issue":"1","key":"5138_CR12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40900-023-00474-x","volume":"9","author":"AH Talal","year":"2023","unstructured":"Talal AH, George SJ, Talal LA, Dharia A, Ventuneac A, Baciewicz G, et al. Engaging people who use drugs in clinical research: integrating facilitated telemedicine for HCV into substance use treatment. Res Involv Engagem. 2023;9(1):63.","journal-title":"Res Involv Engagem"},{"issue":"5","key":"5138_CR13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454\u201363.","journal-title":"N Engl J Med"},{"key":"5138_CR14","volume-title":"The patient satisfaction questionnaire short-form (PSQ-18)","author":"GN Marshall","year":"1994","unstructured":"Marshall GN, Hays RD. The patient satisfaction questionnaire short-form (PSQ-18). Santa Monica, CA: RAND; 1994."},{"key":"5138_CR15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1748-5908-6-118","volume":"6","author":"RE Glasgow","year":"2011","unstructured":"Glasgow RE, Dickinson P, Fisher L, Christiansen S, Toobert DJ, Bender BG, et al. Use of RE-AIM to develop a multi-media facilitation tool for the patient-centered medical home. Implement Sci. 2011;6:118.","journal-title":"Implement Sci"},{"issue":"2","key":"5138_CR16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0738-3991(00)00186-5","volume":"44","author":"RE Glasgow","year":"2001","unstructured":"Glasgow RE, McKay HG, Piette JD, Reynolds KD. The RE-AIM framework for evaluating interventions: what can it tell Us about approaches to chronic illness management? Patient Educ Couns. 2001;44(2):119\u201327.","journal-title":"Patient Educ Couns"},{"issue":"9","key":"5138_CR17","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322\u20137.","journal-title":"Am J Public Health"},{"key":"5138_CR18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.","journal-title":"Implement Sci"},{"issue":"2","key":"5138_CR19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1037\/a0022284","volume":"25","author":"LJ Damschroder","year":"2011","unstructured":"Damschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research in substance use disorders treatment. Psychol Addict Behav. 2011;25(2):194\u2013205.","journal-title":"Psychol Addict Behav"},{"key":"5138_CR20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s43058-020-00023-7","volume":"1","author":"JC Moullin","year":"2020","unstructured":"Moullin JC, Dickson KS, Stadnick NA, Albers B, Nilsen P, Broder-Fingert S, et al. Ten recommendations for using implementation frameworks in research and practice. Implement Sci Commun. 2020;1:42.","journal-title":"Implement Sci Commun"},{"key":"5138_CR21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fpubh.2018.00071","volume":"6","author":"SM Harden","year":"2018","unstructured":"Harden SM, Smith ML, Ory MG, Smith-Ray RL, Estabrooks PA, Glasgow RE. RE-AIM in Clinical, Community, and corporate settings: Perspectives, Strategies, and recommendations to enhance public health impact. Front Public Health. 2018;6:71.","journal-title":"Front Public Health"},{"issue":"5","key":"5138_CR22","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/MLR.0000000000001319","volume":"58","author":"V Yakovchenko","year":"2020","unstructured":"Yakovchenko V, Miech EJ, Chinman MJ, Chartier M, Gonzalez R, Kirchner JE, et al. Strategy configurations directly linked to higher hepatitis C virus treatment starts: an applied use of configurational comparative methods. Med Care. 2020;58(5):e31\u20138.","journal-title":"Med Care"},{"key":"5138_CR23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.pmedr.2017.04.002","volume":"6","author":"J Forman","year":"2017","unstructured":"Forman J, Heisler M, Damschroder LJ, Kaselitz E, Kerr EA. Development and application of the RE-AIM quest mixed methods framework for program evaluation. Prev Med Rep. 2017;6:322\u20138.","journal-title":"Prev Med Rep"},{"issue":"12","key":"5138_CR24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/M16-2887","volume":"166","author":"AH Talal","year":"2017","unstructured":"Talal AH, Thomas DL, Reynolds JL, Khalsa JH. Toward optimal control of hepatitis C virus infection in persons with substance use disorders. Ann Intern Med. 2017;166(12):897\u20138.","journal-title":"Ann Intern Med"},{"issue":"1","key":"5138_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn. 2001;45(1):5\u201332.","journal-title":"Mach Learn"},{"key":"5138_CR26","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"J Mach Learn Res"},{"key":"5138_CR27","unstructured":"Ambuehl M, Baumgartner M, Epple R, Kauffamn A, Thiem A. Nov. CNA: An R package for coincidence analysis (CNA). R. package version 3.5.1. 2015. Available at: http:\/\/CRANR-projectorg\/package=cna. Accessed 5 2022.\u00a0"},{"issue":"1","key":"5138_CR28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13012-020-01070-3","volume":"15","author":"RG Whitaker","year":"2020","unstructured":"Whitaker RG, Sperber N, Baumgartner M, Thiem A, Cragun D, Damschroder L, et al. Coincidence analysis: a new method for causal inference in implementation science. Implement Sci. 2020;15(1):108.","journal-title":"Implement Sci"},{"issue":"6","key":"5138_CR29","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1111\/hex.13854","volume":"26","author":"AH Talal","year":"2023","unstructured":"Talal AH, Jaanimagi U, Dharia A, Dickerson SS. Facilitated telemedicine for hepatitis C virus: addressing challenges for improving health and life for people with opioid use disorder. Health Expect. 2023;26(6):2594\u2013607.","journal-title":"Health Expect"},{"key":"5138_CR30","unstructured":"New York State Office of Addiction Services and Supports. Person-centered care guidance for OASAS certified programs Albany, NY: New York State Office of Addiction Services and Supports; 2018. Available from: https:\/\/oasas.ny.gov\/system\/files\/documents\/2020\/01\/oasasperson-centeredcareguidance.pdf. Accessed 9 Sep 2021."},{"issue":"1","key":"5138_CR31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cld.912","volume":"16","author":"S Arora","year":"2020","unstructured":"Arora S, Thornton K. Novel models of hepatitis C virus care delivery: Telemedicine, project ECHO, and integrative care. Clin Liver Disease. 2020;16(1):5.","journal-title":"Clin Liver Disease"},{"key":"5138_CR32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 2","key":"5138_CR33","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/cit263","volume":"57","author":"C Treloar","year":"2013","unstructured":"Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis. 2013;57(Suppl 2):S51\u20135.","journal-title":"Clin Infect Dis"},{"key":"5138_CR34","doi-asserted-by":"crossref","first-page":"e53049","DOI":"10.2196\/53049","volume":"26","author":"SS Dickerson","year":"2024","unstructured":"Dickerson SS, George SJ, Ventuneac A, Dharia A, Talal AH. Care integration for hepatitis C virus treatment through facilitated telemedicine within opioid treatment programs: qualitative study. J Med Internet Res. 2024;26:e53049.","journal-title":"J Med Internet Res"},{"key":"5138_CR35","unstructured":"Heath B, Wise Romero P, Reynolds KA. A standard framework for levels of integrated healthcare. Washington, D.C.: SAMHSA-HRSA Center for Integrated Health Solutions; 2013. Available at: https:\/\/www.thenationalcouncil.org\/wp-content\/uploads\/2020\/01\/CIHS_Framework_Final_charts.pdf?daf=375ateTbd56. Accessed 3 Jan 2021."},{"issue":"8","key":"5138_CR36","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.mayocp.2023.04.013","volume":"98","author":"J Le-Rademacher","year":"2023","unstructured":"Le-Rademacher J, Gunn H, Yao X, Schaid DJ. Clinical trials overview: from explanatory to pragmatic clinical trials. Mayo Clin Proc. 2023;98(8):1241\u201353.","journal-title":"Mayo Clin Proc"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05138-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-025-05138-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05138-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:24:01Z","timestamp":1760523841000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-025-05138-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5138"],"URL":"https:\/\/doi.org\/10.1186\/s12906-025-05138-9","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board at the University at Buffalo (parent institution), and by the Institutional Review Boards at each participating site. All participants provided informed consent. The ethical approval number is MODCR00009273.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AHT received grant support from the Patient-Centered Outcomes Research Institute (PCORI), Kaleida Health Foundation, Gilead Sciences, Merck, Eli Lilly, BMS, GENFIT, AbbVie, Novo Nordisk, and Intercept. MM received grant support from PCORI and Kaleida Health Foundation. JNT received grant support from the National Institutes of Health\/National Heart, Lung, and Blood Institute and the Department of Health and Human Services\u2019 Administration for Community Living.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}